Diabetes often leads to long term complications, which affect many tissues, including the heart, nerves, kidney and eyes. Elevated glucose levels in tissues leads to generation of toxic byproducts in both Type I and Type II diabetes. The enzyme Aldose Reductase plays a key role in production of toxic metabolites that cause diabetic complications.
Animal models have supported the role of Aldose Reductase in development of diabetic complications. Additionally, diabetic patients that have higher levels of Aldose Reductase are more likely to develop diabetic complications. Blocking this enzyme has been shown to decrease diabetic complications animal models and has been shown to be beneficial in patients with diabetes.
Diabetes increases patients’ risk of heart failure. One type of heart failure that develops in diabetic patients is called Diabetic Cardiomyopathy, or DbCM. Diabetic Cardiomyopathy can develop in diabetic patients due to metabolic changes, and may develop independently from hypertension (high blood pressure) or coronary artery disease. Up to 25% of diabetic patients may develop Diabetic Cardiomyopathy.
For relevant literature and scientific publications, please visit the links below: